Promising drug combo for tough breast cancer hits roadblock

NCT ID NCT03289039

Terminated Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jan 23, 2026 · Last updated Apr 25, 2026 · Updated 7 times

Summary

This study tested a drug called neratinib, alone or with another drug (fulvestrant), in people with a specific advanced breast cancer (HER2-positive and ER-positive). The goal was to see if the combination could slow cancer growth. The study was stopped early after enrolling 21 participants, so results are limited. It was a phase 2 trial, meaning it was still checking safety and effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Dana-Farber/New Hampshire Oncology-Hematology

Londonderry, New Hampshire, 03053, United States
Eastern Maine Medical Center

Brewer, Maine, 04412, United States
Indiana University

Indianapolis, Indiana, 46202, United States
The Ohio State University

Columbus, Ohio, 43210, United States
UT Southwestern

Dallas, Texas, 75390, United States

Conditions

Explore the condition pages connected to this study.

BREAST CANCER